potent
invitro
effect
hydroxychloroquin
hcq
convincingli
translat
clinic
benefit
patient
nonrandom
trial
show
significantli
higher
viru
clearanc
rate
post
inclus
patient
receiv
hydroxychloroquin
daili
patient
standardofcar
contrast
random
studi
hydroxychloroquin
publish
chines
show
impact
hydroxychloroquin
dose
hydroxychloroquin
daili
day
increas
viru
neg
convers
rate
allevi
clinic
symptom
patient
multicent
parallel
openlabel
random
trial
includ
adult
patient
hospit
ad
hydroxychloroquin
current
standardofcar
patient
increas
viru
respons
acceler
allevi
clinic
symptom
possibl
antiinflammatori
properti
recoveri
lymphopenia
clinician
might
consid
hydroxychloroquin
treatment
symptomat
patient
elev
crp
andor
lymphopenia
hydroxychloroquin
might
prevent
diseas
progress
particularli
patient
higher
risk
side
effect
hcq
close
monitor
although
appar
safeti
concern
observ
trial
use
hcq
load
dose
mg
daili
three
day
follow
maintain
dose
mg
daili
remain
day
total
treatment
durat
week
mildmoder
sever
patient
respect
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
swept
countri
area
territori
within
four
month
april
million
infect
thousand
death
report
sever
agent
drug
includ
remdesivir
favipiravir
ribavirin
lopinavirritonavir
use
combin
chloroquin
cq
hydroxychloroquin
hcq
highlight
base
promis
invitro
result
therapeut
experi
anoth
two
coronaviru
diseas
includ
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
howev
none
promis
result
yet
translat
clinic
benefit
patient
includ
lopinavirritonavir
report
recent
fail
trial
anoth
wonder
drug
cq
hydroxyanalogu
hcq
glare
list
therapi
due
potent
antivir
activ
invitro
studi
promis
result
news
report
ongo
trial
despit
unclear
benefit
cq
hcq
recommend
offlabel
use
treatment
chines
nation
guidelin
recent
author
us
food
drug
administr
emerg
use
hcq
also
recent
recommend
american
presid
donald
trump
presidenti
endors
stimul
avalanch
demand
hcq
buri
darksid
drug
death
report
nigeria
among
peopl
selftreat
appar
cq
overdos
retinopathi
gastrointestin
cardiac
side
effect
well
document
use
cq
hcq
treatment
malari
rheumat
diseas
hcq
prefer
clinic
applic
due
lower
toxic
particularli
retin
toxic
three
time
potenc
infect
compar
cq
recent
invitro
studi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
current
convinc
evid
welldesign
clinic
trial
support
use
cqhcq
good
efficaci
safeti
treatment
rapidli
conduct
trail
highqual
challeng
face
danger
coronaviru
outbreak
healthcar
worker
overwhelm
work
highest
risk
exposur
develop
encount
numer
challeng
conduct
multicent
openlabel
random
control
trial
assess
efficaci
safeti
hcq
sulfat
adult
patient
clearer
verdict
come
trial
use
hcq
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
design
initi
princip
investig
protocol
approv
institut
review
board
ruijin
hospit
conduct
urgent
outbreak
complianc
declar
helsinki
good
clinic
practic
guidelin
local
regulatori
requir
shanghai
pharmaceut
hold
co
ltd
donat
investig
drug
hcq
involv
studi
design
accrual
analys
data
prepar
manuscript
contract
research
organ
cro
r
g
pharmastudi
co
ltd
hire
conduct
studi
collect
data
perform
statist
analys
data
record
clinic
research
coordin
follow
queri
clinic
research
associ
confirm
data
enter
webbas
openclinica
databas
statist
analys
independ
data
safeti
monitor
committe
idmc
period
review
progress
oversight
studi
hospit
capabl
provid
current
soc
invit
particip
studi
princip
investig
minimum
requir
soc
includ
provis
intraven
fluid
supplement
oxygen
regular
laboratori
test
test
hemodynam
monitor
intens
care
abil
deliv
concomit
medic
interim
analysi
perform
march
result
present
idmc
review
data
review
idmc
conclud
trial
take
consider
good
efficaci
hcq
symptom
allevi
antiinflamm
report
interim
analysi
member
idmc
trial
princip
investig
decid
report
trial
result
promot
translat
promis
result
clinic
benefit
could
save
live
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
emerg
ongo
pandem
particularli
overwhelm
area
manuscript
draft
base
result
first
last
author
great
input
coauthor
author
vouch
verac
data
analys
trial
protocol
vouch
trial
conduct
report
consist
protocol
togeth
statist
analysi
plan
avail
appendix
studi
multicent
random
parallel
openlabel
trial
oral
hcq
hospit
patient
placebo
use
drug
mask
patient
meet
elig
criteria
stratifi
accord
diseas
sever
mildmoder
sever
randomli
assign
ratio
receiv
either
soc
soc
plu
hcq
patient
enrol
site
investig
statistician
perform
random
equal
number
card
group
assign
number
randomli
gener
comput
place
sequenti
number
envelop
open
patient
enrol
patient
treat
soc
align
indic
updat
nation
clinic
practic
guidelin
china
treatment
hcq
begun
within
hour
random
administr
load
dose
mg
daili
three
day
follow
maintain
dose
mg
daili
remain
day
total
treatment
durat
week
week
mildmoder
sever
patient
respect
dose
hcq
adjust
advers
event
relat
hcq
judg
investig
detail
dose
adjust
provid
studi
protocol
avail
onlin
neither
patient
investig
statistician
mask
treatment
assign
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
enrol
governmentdesign
treatment
center
three
provinc
china
hubei
henan
anhui
provinc
februari
februari
patient
provid
written
inform
consent
elig
patient
least
year
age
ongo
infect
confirm
realtim
reversetranscriptasepolymerasechainreact
rtpcr
patient
will
particip
trial
consent
enrol
clinic
trial
studi
period
chest
comput
tomographi
examin
result
need
determin
diseas
sever
random
patient
receiv
hcq
oral
patient
known
allergi
hcq
exist
condit
could
lead
sever
advers
event
trial
period
exclud
particularli
sever
liver
renal
diseas
could
impair
abil
metabol
high
dose
hcq
unabl
cooper
investig
due
cognit
impair
poor
mental
statu
consid
inappropri
trial
femal
patient
pregnant
lactat
period
exclud
full
elig
criteria
provid
protocol
appendix
upper
andor
lower
respiratori
tract
specimen
obtain
patient
upon
screen
day
treatment
posttreat
followup
schedul
visit
day
collect
specimen
test
determin
posit
neg
result
site
local
center
diseas
control
prevent
accord
recommend
patient
assess
schedul
visit
vital
sign
creactiv
protein
crp
erythrocyt
sediment
rate
esr
tumor
necrosi
factor
tnf
complet
blood
cell
count
differenti
blood
chemistri
coagul
panel
puls
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
oximetri
respiratori
symptom
administr
record
hcq
advers
event
review
daili
ensur
fidel
protocol
importantli
patient
safeti
detail
data
collect
provid
protocol
appendix
primari
endpoint
trial
neg
convers
within
key
secondari
endpoint
includ
allevi
clinic
symptom
laboratori
paramet
chest
radiolog
within
definit
allevi
clinic
symptom
resolv
fever
axillari
temperatur
normal
room
air
disappear
respiratori
symptom
includ
nasal
congest
cough
sore
throat
sputum
product
short
breath
normal
laboratori
paramet
focus
crp
esr
level
secondari
outcom
sever
case
includ
allcaus
mortal
clinic
statu
assess
sixcategori
ordin
scale
day
day
mechan
ventil
extracorpor
membran
oxygen
supplement
oxygen
hospit
stay
sever
case
diseas
progress
assess
mildmoder
case
safeti
outcom
includ
advers
event
occur
studi
period
advers
event
code
use
latest
version
medic
dictionari
regulatori
activ
code
dictionari
record
standard
medic
terminolog
grade
accord
nation
cancer
institut
common
terminolog
criteria
advers
event
overal
neg
convers
rate
estim
compar
analyz
time
viru
nucleic
acid
neg
use
kaplanmei
method
intentiontotreat
popul
hazard
ratio
estim
cox
model
higher
rapid
convers
approach
appli
analyz
key
secondari
endpoint
forest
plot
use
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
display
hazard
ratio
gener
subgroup
trial
design
enrol
approxim
subject
per
group
assur
power
familywis
typei
error
sampl
size
calcul
base
altern
hypothesi
increas
speed
viru
nucleic
acid
neg
therefor
total
event
need
logrank
test
interim
analysi
plan
around
patient
treat
least
day
obrienflem
cumul
spend
function
landemet
algorithm
landemet
appli
control
familywis
typei
error
absolut
chang
baselin
crp
blood
lymphocyt
count
last
assess
compar
actual
treatment
group
use
twosampl
ttest
signific
claim
analys
primari
analysi
pvalu
data
analys
conduct
sa
version
random
control
trial
involv
patient
trial
design
outcom
measur
data
analysi
result
interpret
manuscript
write
person
health
inform
use
trial
access
patient
public
studi
protocol
avail
onlin
supplementari
materi
public
paper
preprint
version
studi
publicli
avail
medrxiv
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
total
patient
admit
februari
februari
assess
elig
meet
elig
criteria
remain
patient
underw
random
among
patient
assign
soc
patient
soc
plu
hcq
group
figur
mean
age
patient
year
male
mean
day
diseas
onset
random
patient
concomit
medic
random
major
patient
mild
moder
patient
sever
upon
screen
baselin
demograph
epidemiolog
clinic
characterist
patient
two
group
shown
tabl
march
cutoff
date
data
analysi
median
durat
followup
day
rang
soc
group
day
rang
soc
plu
hcq
group
patient
assign
receiv
soc
plu
hcq
patient
receiv
dose
hcq
patient
withdrew
consent
patient
refus
administr
hcq
overal
neg
convers
rate
among
patient
assign
receiv
soc
plu
hcq
confid
interv
ci
similar
soc
group
ci
within
neg
convers
rate
specif
timepoint
also
similar
two
group
neg
convers
time
differ
soc
plu
hcq
soc
group
median
day
vs
day
hazard
ratio
ci
figur
post
hoc
analys
perform
subgroup
explor
decreas
neg
convers
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
time
addit
hcq
upon
soc
effect
observ
analyz
subgroup
accord
age
year
versu
year
bmi
valu
kgm
versu
kgm
presenc
absenc
exist
condit
day
diseas
onset
random
day
versu
day
baselin
crp
valu
limit
normal
versu
upper
limit
normal
baselin
lymphocyt
count
lower
limit
normal
versu
lower
limit
normal
without
contamin
use
potenti
antivir
agent
treat
studi
period
figur
b
overal
rate
symptom
allevi
within
figur
b
compar
soc
alon
addit
hcq
soc
led
rapid
normal
elev
baselin
crp
recoveri
baselin
lymphocytopenia
although
overal
improv
rate
becom
similar
within
figur
b
declin
valu
crp
baselin
last
assess
significantli
greater
soc
plu
hcq
group
soc
group
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
absolut
chang
versu
milligramlit
figur
similarli
elev
blood
lymphocyt
count
last
assess
baselin
greater
soc
plu
hcq
group
soc
group
absolut
chang
versu
liter
figur
comprehens
analysi
prespecifi
secondari
outcom
includ
reduct
erythrocyt
sediment
rate
avail
due
limit
data
paramet
prespecifi
visit
date
six
patient
assign
soc
plu
hcq
group
receiv
hcq
treatment
classifi
hcq
nonrecipi
safeti
popul
one
patient
soc
group
wrongli
receiv
hcq
treatment
accumul
dose
mg
patient
classifi
hcq
recipi
safeti
popul
figur
safeti
endpoint
compar
hcq
recipi
nonrecipi
tabl
hcq
recipi
median
durat
hcq
treatment
day
rang
random
final
visit
total
patient
soc
plu
hcq
group
report
advers
event
significantli
higher
patient
report
soc
group
tabl
common
advers
event
soc
plu
hcq
group
diarrhea
frequent
soc
group
versu
hcq
discontinu
one
patient
due
blur
vision
adjust
give
lower
dose
one
patient
report
thirst
two
advers
event
transient
period
day
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
neg
result
antivir
efficaci
hcq
obtain
trial
contrari
encourag
invitro
result
recent
report
promis
result
nonrandom
trial
patient
interpret
result
note
precis
antivir
mechan
cqhcq
establish
virus
discrep
result
trial
invitro
studi
highlight
import
preclin
invivo
studi
pharmacokinet
pharmacodynam
toxic
profil
test
drug
establish
although
data
cqhcq
anim
studi
data
mice
studi
suggest
limit
efficaci
cq
inhibit
sarscov
replic
promis
antivir
result
hcq
recent
trial
interpret
caution
due
limit
sampl
size
lack
random
design
combin
therapi
hcq
plu
azithromycin
recommend
author
base
viru
neg
convers
rate
within
one
week
treatment
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
unabl
valid
result
due
limit
number
patient
use
azithromycin
contrast
excel
effect
result
support
clinic
use
hcq
suppress
viral
replic
one
might
argu
median
delay
hcq
treatment
symptom
onset
studi
longer
time
window
effect
treatment
virusrel
respiratori
diseas
like
influenza
howev
subgroup
patient
receiv
hcq
within
ill
onset
addit
viru
neg
convers
rate
observ
beyond
soc
trial
challeng
conduct
trial
hospit
patient
within
ill
onset
due
estim
day
delay
ill
onset
hospit
admiss
futur
trial
consid
enrol
patient
earlystag
outpati
clinic
one
might
also
argu
current
soc
includ
antivir
sourc
confound
effect
although
none
yet
proven
efficaci
treat
nevertheless
differ
regard
time
viru
neg
convers
treatment
control
group
observ
exclud
patient
ever
receiv
antivir
studi
period
includ
lopinavirritonavir
arbidol
oseltamivir
virazol
entecavir
ganciclovir
andor
interferonalpha
note
promis
drug
lopinavirritonavir
inhibitor
hiv
proteas
recent
demonstr
ineffect
lower
viru
load
moreov
specimen
collect
trial
viru
rna
determin
mostli
upper
respiratori
tract
introduc
falseneg
result
bronchoalveolar
lavag
fluid
best
specimen
detect
well
collect
sinc
major
patient
mildmoder
case
without
need
bronchoscopi
prespecifi
definit
viru
neg
convers
two
neg
least
hour
apart
could
significantli
reduc
fals
neg
although
monitor
concentr
hcq
studi
dosag
choos
enough
reach
effect
concentr
ec
hcq
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
therefor
like
addit
antivir
effect
escal
dosag
taken
togeth
futur
studi
could
take
advantag
result
design
trial
select
popul
earliest
stage
possibl
ill
onset
use
sensit
endpoint
viral
load
shed
also
remain
open
question
whether
hcq
would
lead
improv
virolog
respons
patient
sever
addit
viru
infect
acut
inflamm
respons
anoth
hallmark
covid
recent
find
clinic
seri
shown
system
inflamm
cytokin
storm
driver
diseas
progress
death
substanti
decreas
lymphocyt
count
increas
inflammatori
respons
marker
eg
crp
observ
earli
stage
patient
eventu
progress
die
result
highlight
import
recoveri
lymphopenia
antiinflamm
prevent
develop
system
inflamm
critic
ill
patient
abil
benefit
observ
hcq
current
trial
show
patient
soc
plu
hcq
significantli
greater
reduct
crp
level
moder
elev
blood
lymphocyt
count
last
assess
compar
patient
soc
effect
observ
hcq
treatment
maintain
withdraw
hcq
encourag
result
suggest
clinic
benefit
ad
hcq
current
standard
manag
limit
inflammatori
respons
key
prevent
system
inflamm
subsequ
multipl
organ
failur
death
mechan
perspect
hcq
weak
base
accumul
within
acid
vesicl
lysosom
autophagosom
phagocyt
cell
chang
local
ph
valu
subsequ
inhibit
immun
activ
multipl
cellular
function
molecular
pathway
partial
inhibit
mhc
class
ii
express
antigen
present
tolllik
signal
pathway
product
tnf
shred
evid
support
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
antiinflammatori
effect
hcq
observ
studi
patient
given
hcq
load
dose
mg
daili
three
day
follow
maintain
dose
mg
daili
remain
day
total
treatment
durat
week
week
mildmoder
sever
patient
respect
lower
dose
shorter
treatment
durat
recommend
previou
studi
use
mg
hcq
per
day
day
show
addit
effect
allevi
symptom
viral
suppress
howev
remain
determin
whether
extens
treatment
durat
would
bring
benefit
hcq
gradual
onset
action
might
take
week
reach
maxim
activ
also
import
explor
combin
therapi
hcq
antiinflammatori
drug
higher
dosag
hcq
treatment
patient
anoth
encourag
result
studi
use
current
hcq
regimen
seriou
sideeffect
rare
patient
well
toler
consist
previou
report
cancer
studi
use
hcq
dose
mg
daili
transient
blur
vision
report
one
patient
trial
retin
damag
assess
use
autom
visual
field
spectraldomain
optic
coher
tomographi
recommend
screen
retinopathi
although
retin
toxic
effect
hcq
dosag
mgkg
less
year
earlier
develop
retin
damag
daili
dose
detect
use
sensit
retin
screen
test
therefor
retin
damag
could
underestim
trial
evid
increas
rate
advers
gastrointestin
event
high
dose
hcq
observ
trial
particularli
increas
burden
diarrhea
event
cardiac
arrhythmia
eg
prolong
qt
interv
observ
trial
possibl
due
rel
mildmoder
patient
investig
shortterm
period
followup
howev
increas
interest
combin
use
hcq
azithromycin
worldwid
physician
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
cautiou
increas
risk
qt
interv
prolong
fatal
ventricular
arrhythmia
azithromycin
antimicrobi
overal
gener
favor
safeti
profil
hcq
use
current
regimen
support
futur
explor
clinic
benefit
provid
drug
howev
drugdrug
interact
wuhan
neighbor
citi
nationwid
travel
restrict
casecontact
isol
also
barrier
collect
transfer
data
paper
file
prespecifi
secondari
endpoint
imag
chang
chest
ct
therefor
finish
cutoff
date
analysi
recruit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
conclus
result
trial
show
addit
virolog
respons
ad
hcq
current
soc
administr
hcq
load
dose
mg
daili
three
day
follow
maintain
dose
mg
daili
remain
day
total
treatment
durat
week
week
mildmoder
sever
patient
respect
clearli
associ
greater
declin
crp
recoveri
lymphopenia
higher
rate
symptom
allevi
result
appar
safeti
concern
patient
hospit
welltoler
cheap
wide
avail
drug
futur
trial
determin
clinic
benefit
hcq
prevent
diseas
progress
critic
import
consid
ongo
pandem
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
data
collect
data
analysi
data
interpret
report
guarantor
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
final
respons
decis
submit
public
compet
interest
author
complet
icmj
uniform
disclosur
form
wwwicmjeorgcoidisclosurepdf
declar
support
organ
submit
work
financi
relationship
organ
might
interest
submit
work
previou
three
year
relationship
activ
could
appear
influenc
submit
work
patient
consent
written
inform
consent
obtain
data
share
anonym
dataset
made
avail
reason
request
approv
trial
manag
committe
sign
data
access
agreement
propos
direct
correspond
author
lead
author
manuscript
guarantor
affirm
manuscript
honest
accur
transpar
account
studi
report
import
aspect
studi
omit
discrep
studi
plan
relev
regist
explain
random
control
trial
involv
patient
trial
design
outcom
measur
data
analysi
result
interpret
manuscript
write
person
health
inform
use
trial
access
patient
public
studi
protocol
avail
onlin
supplementari
materi
public
paper
preprint
version
studi
publicli
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
avail
medrxiv
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
figur
absolut
chang
crp
lymphocyt
count
baselin
last
assess
patient
shown
bar
chart
absolut
chang
crp
blood
lymphocyt
count
last
assess
compar
baselin
valu
patient
soc
without
hcq
data
express
mean
standard
error
mean
declin
valu
crp
baselin
last
assess
significantli
greater
soc
plu
hcq
group
soc
group
chang
versu
milligramlit
elev
blood
lymphocyt
count
last
assess
baselin
greater
soc
plu
hcq
group
soc
group
chang
versu
liter
without
statist
signific
patient
baselin
last
assess
calcul
valu
chang
analysi
avail
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
number
patient
group
provid
bracket
socstandardofcar
hcqhydroxychloroquin
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
nasal
congest
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
